Cocrystal Pharma Inc has a consensus price target of $10 based on the ratings of 1 analysts. The high is $10 issued by HC Wainwright & Co. on May 14, 2024. The low is $10 issued by HC Wainwright & Co. on May 14, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 14, 2024, April 4, 2024, and March 20, 2024, respectively. With an average price target of $10 between HC Wainwright & Co., there's an implied 340.53% upside for Cocrystal Pharma Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/14/2024 | Buy Now | 340.53% | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | Buy → Buy | Get Alert |
04/04/2024 | Buy Now | 340.53% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
03/20/2024 | Buy Now | 340.53% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
01/03/2024 | Buy Now | 340.53% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $10 | Maintains | Buy | Get Alert |
12/04/2023 | Buy Now | 428.63% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
10/04/2023 | Buy Now | 428.63% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
08/15/2023 | Buy Now | 428.63% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 428.63% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
06/02/2023 | Buy Now | 428.63% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
05/24/2023 | Buy Now | 428.63% | HC Wainwright & Co. | Raghuram Selvaraju | $35 → $12 | Maintains | Buy | Get Alert |
01/24/2023 | Buy Now | 1441.85% | HC Wainwright & Co. | Raghuram Selvaraju | $42 → $35 | Maintains | Buy | Get Alert |
11/07/2022 | Buy Now | 1750.22% | HC Wainwright & Co. | Raghuram Selvaraju | $4 → $42 | Maintains | Buy | Get Alert |
The latest price target for Cocrystal Pharma (NASDAQ:COCP) was reported by HC Wainwright & Co. on May 14, 2024. The analyst firm set a price target for $10.00 expecting COCP to rise to within 12 months (a possible 340.53% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Cocrystal Pharma (NASDAQ:COCP) was provided by HC Wainwright & Co., and Cocrystal Pharma reiterated their buy rating.
There is no last upgrade for Cocrystal Pharma
There is no last downgrade for Cocrystal Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cocrystal Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cocrystal Pharma was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
While ratings are subjective and will change, the latest Cocrystal Pharma (COCP) rating was a reiterated with a price target of $10.00 to $10.00. The current price Cocrystal Pharma (COCP) is trading at is $2.27, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.